°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

Àü±â¿µµ¿ ½Ã¾à ½ÃÀå : ¼ºÀå, µ¿Çâ, COVID-19ÀÇ ¿µÇâ, ¿¹Ãø(2021-2026³â)

Electrophoresis Reagents Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

¸®¼­Ä¡»ç Mordor Intelligence Pvt Ltd
¹ßÇàÀÏ 2021³â 03¿ù »óǰ ÄÚµå 707230
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 4,250 £Ü 4,788,000 PDF (Single User License)
US $ 4,750 £Ü 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 £Ü 6,760,000 PDF (Site License)
US $ 7,500 £Ü 8,451,000 PDF (Corporate License)


Àü±â¿µµ¿ ½Ã¾à ½ÃÀå : ¼ºÀå, µ¿Çâ, COVID-19ÀÇ ¿µÇâ, ¿¹Ãø(2021-2026³â) Electrophoresis Reagents Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)
¹ßÇàÀÏ : 2021³â 03¿ù ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àü±â¿µµ¿ ½Ã¾à(Electrophoresis Reagents) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, Á¦Ç°¡¤±â¼ú¡¤ÃÖÁ¾»ç¿ëÀÚ¡¤Áö¿ªº° ½ÃÀå ±Ô¸ð ÃßÁ¤°ú ¿¹Ãø, ½ÃÀå µ¿Çâ, ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ ºÐ¼®, Porter's Five Forces ºÐ¼®, °æÀï »óȲ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • ½ÃÀå Á¤ÀÇ

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ÁÖ¿ä ¿µÇâ¿äÀÎ

Á¦5Àå Àü±â¿µµ¿ ½Ã¾à ½ÃÀå °³¿ä

  • ÇöÀç ½ÃÀå ½Ã³ª¸®¿À
  • Porter's Five Forces ºÐ¼®
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±Þ ±â¾÷ÀÇ Çù»ó·Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦6Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
    • °Ô³ð ¹× ÇÁ·ÎÅ×¿È ¿¬±¸¸¦ À§ÇÑ ÀÚ±Ý Á¶´Þ Áõ°¡
    • ¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½Â
    • »êÇÐ Á¦ÈÞ È®´ë
    • ±â¼ú °³¹ß
  • ¼ºÀå ÀúÇØ¿äÀÎ
    • ½Ã°£ÀÌ ¼Ò¸ðµÇ´Â Á¶ÀÛ
    • ´ëü ±â¼úÀÇ Á¸Àç
  • ½ÃÀå ±âȸ
  • °úÁ¦

Á¦7Àå ½ÃÀå ºÐ¼® : ºÎ¹®º°

  • Á¦Ç°º°
    • °Ö
    • ¿°·á
    • ¿ÏÃæ¾×
    • ±âŸ ½Ã¾à
  • ±â¼úº°
    • °Ö Àü±â¿µµ¿
    • ¸ð¼¼°ü Àü±â¿µµ¿
  • ÃÖÁ¾»ç¿ëÀÚº°
    • Çмú ¹× ¿¬±¸±â°ü
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ¿¬±¸¼Ò
    • ±âŸ
  • Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì

Á¦8Àå ±â¾÷ °³¿ä¿Í °æÀï »óȲ

  • Agilent Technologies, Inc.
  • BioAtlas
  • Bio-Rad Laboratories, Inc.
  • GE Healthcare
  • Lonza Group, AG
  • Merck KGaA
  • Qiagen NV
  • Sigma-Aldrich Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific

Á¦9Àå ½ÃÀåÀÇ ÇâÈÄ Àü¸Á

KSM 18.10.05

The Electrophoresis Reagents Market was valued at USD 981.40 million in 2020 and is expected to reach USD 1,318.99 million by 2026, registering a CAGR of 5.11 % during the forecast period.

Globally, the outbreak of COVID-19 was an incomparable public health emergency that has affected almost every industry. The COVID-19 has shown a positive impact on the market growth because the electrophoresis technique has been used in the development of effective therapies as this is used to separate DNA, RNA, or protein molecules based on their size in the development of effective therapies for COVID-19.

For instance, as per National Clinical Trial (NCT) Registry, Elsan is conducting clinical trial to assess serum inflammation profiles by protein electrophoresis on patients hospitalized for an infection with the SARS-CoV-2 virus. Thus, increasing research and development activities in the development of effective therapies is expected to increase the demand for electrophoresis reagents in near future.

The major factors driving the growth of the electrophoresis reagents market include the increasing funding for genomic and proteomic research, rising prevalence of chronic diseases, increasing collaborations between industry and academics, and technological developments.

According to the World Health Organization (WHO), in 2020, the prevalence of chronic diseases was increased by 57%. Additionally, as per International Diabetes Federation (IDF) 2020, globally, there were around 463 million people with diabetes in 2020 and 88 million people in the Southeast Asia region. In India, there were around 77 million with diabetes. The prevalence of diabetes in the population is 8.9%.

Furthermore, with the increasing cases of chronic diseases such as diabetes, prompt diagnosis and treatment are in need. Therefore, this has given rise to the electrophoresis that is used in the clinical laboratories to quantify the lipoproteins using enzymatic staining of cholesterol and triglycerides for the diagnosis of cardiovascular diseases and other chronic diseases, like diabetes.

The electrophoresis is used in the analysis of the lipoproteins and apolipoproteins that are essential for the valuation of the cardiovascular diseases and monitoring of individuals on treatment. Furthermore, the development of this market is also significantly determined by the expanding research exercises in the fields of proteomics and genomics, changing administrative necessities in the pharmaceutical part, and the developing need to reduce the healthcare expenses.

Therefore, factors like rising per capita income and increasing public healthcare expenditure are also expected to promote the growth of electrophoresis reagents market over the forecast period.

Key Market Trends

Gel Electrophoresis is Expected to Hold a Major Market Share in the Electrophoresis Reagents Market

The major factors driving the gel electrophoresis segment include low operating and instrument cost, rising applications in the pharmaceutical and biotechnology industries, and the increasing burden of infectious diseases, cancer, and genetic disorders.

There has been increasing use of gel-electrophoresis along with RT-PCR assays for the detection of SARS-CoV-2. For instance, a research article by Wischmann F-J et al., published in 2020, stated that the use of gel-electrophoresis in combination with conventional PCR for test analysis is a feasible approach to make SARS-CoV-2 diagnostic available in the whole world.

Gel electrophoresis is a separation technique and analysis of macromolecules such as RNA, DNA, and proteins and their fragments based on their charge and size. It is used in clinical chemistry to separate proteins and also used in molecular biology and biochemistry to separate a mixed population of RNA and DNA fragments by length among others.

The prevalence of various chronic diseases such as cancer, neurological diseases, and cardiovascular diseases is increasing across the world. For instance, as per International Agency for Research, estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. In addition, as per Globocan data, in 2020, the number of cancer cases was risen to 19.3 million and 10 million deaths were due to cancer.

Globally, there is rise in the number of prostate cancer, breast cancer, and cervical cancers. The rising incidence of such diseases is increasing the demand for new diagnostic procedures and the development of novel therapeutic medicines, which in turn, is driving the growth of the gel electrophoresis segment. Hence, owing to the above factors the segment is expected to boost in the coming years.

Asia-Pacific Region is the Fastest Growing Market and is Expected to Follow the Same Trend Over the Forecast Period

The Asia-Pacific region is expected to be the fastest-growing market. In the emerging economies of China, Japan, and India, there has been an increasing number of research activities going on in academic and research institutions, pharmaceutical, and biotechnology companies, and increasing adoption of advanced technology and rising health awareness are some of the key factors contributing to the market growth.

Japanese Scientists have developed a new method for identifying single virus particles based on changes in electrical current through the electrophoresis process. For instance, in 2020, scientists from Osaka University developed a new method for fast and accurate screening tests in the diagnosis of diseases like COVID-19 and influenza. Thus, increasing research and development activities in the development of new diagnostic approaches based on electrophoresis techniques is expected to raise the demand for reagents and drives market growth.

The high growth is also majorly attributed to the rapidly improving healthcare infrastructure and low labor costs in emerging countries. According to the World Health Organization (WHO) 2018 report, estimates that chronic diseases such as cardiovascular, chronic respiratory diseases, diabetes and cancer were top killers in the South-East Asia Region, claiming an estimated 8.5 million lives each year.

The demand for electrophoresis reagents to surge in Asia-Pacific market as increasing application of capillary electrophoresis in microbial detection driving electrophoresis reagents market. Increasing complexities in the treatment of diseases such as cancer, genetic diseases and other health issues, is also one of the factors fuelling the growth of the electrophoresis reagents market.

Furthermore, the application of capillary electrophoresis in areas such as microbial detection and protein analysis is boosting the popularity of capillary electrophoresis and driving market growth. Thus, owing to the above factors the market is expected to grow rapidly in the coming years.

Competitive Landscape

The Electrophoresis Reagents Market is moderately fragmented and competitive. The major players are found adopting various strategies, such as agreements, expansion, contracts, partnerships, new reagent development, joint ventures, and mergers and acquisitions in order to strengthen their position in the electrophoresis reagents market. Some of the companies which are currently dominating the market are Agilent Technologies Inc., BioAtlas, Bio-Rad Laboratories Inc., Cytiva, Lonza Group AG, Merck KGaA, Qiagen NV, Sigma-Aldrich Corporation, Takara Bio Inc. and Thermo Fisher Scientific.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Funding for Genomic and Proteomic Research
    • 4.2.2 Rising Prevalence of Chronic Diseases
    • 4.2.3 Technological Developments
  • 4.3 Market Restraints
    • 4.3.1 Time-consuming Operations
    • 4.3.2 Presence of Alternative Technologies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Gels
      • 5.1.1.1 Agarose Gels
      • 5.1.1.2 Polyacrylamide Gels
      • 5.1.1.3 Starch Gels
    • 5.1.2 Dyes
      • 5.1.2.1 Ethidium Bromide (ETBR) Dyes
      • 5.1.2.2 Bromophenol Blue
      • 5.1.2.3 Sybr Dyes
      • 5.1.2.4 Other Dyes
    • 5.1.3 Buffers
      • 5.1.3.1 Tris/Acetate/EDTA
      • 5.1.3.2 Tris/Borate/EDTA
      • 5.1.3.3 Other Buffers
    • 5.1.4 Other Products
  • 5.2 By Technique
    • 5.2.1 Gel Electrophoresis
    • 5.2.2 Capillary Electrophoresis
  • 5.3 By End User
    • 5.3.1 Academic and Research Institutions
    • 5.3.2 Pharmaceutical and Biotechnology Companies
    • 5.3.3 Laboratories
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 BioAtlas
    • 6.1.3 Bio-Rad Laboratories Inc.
    • 6.1.4 Cytiva
    • 6.1.5 Lonza Group AG
    • 6.1.6 Merck KGaA
    • 6.1.7 Qiagen NV
    • 6.1.8 Sigma-Aldrich Corporation
    • 6.1.9 Takara Bio Inc.
    • 6.1.10 Thermo Fisher Scientific
    • 6.1.11 Promega Corporation
    • 6.1.12 Hoefer Inc. (Harvard Bioscience Inc)
    • 6.1.13 Sebia Group
    • 6.1.14 Randox Laboratories Ltd
    • 6.1.15 Helena Laboratories Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q